SEC Info℠  
    Home      Search      My Interests      Help      Sign In      Please Sign In

TRxADE HEALTH, Inc. – ‘10-Q’ for 3/31/21 – ‘EX-101.INS’

On:  Monday, 4/26/21, at 4:06pm ET   ·   For:  3/31/21   ·   Accession #:  1493152-21-9653   ·   File #:  1-39199

Previous ‘10-Q’:  ‘10-Q’ on 10/26/20 for 9/30/20   ·   Next:  ‘10-Q’ on 7/26/21 for 6/30/21   ·   Latest:  ‘10-Q’ on 1/16/24 for 9/30/23   ·   2 References:   

Find Words in Filings emoji
 		  in    Show  and   ↓Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 4/26/21  Trxade Group, Inc.                10-Q        3/31/21   53:2.6M                                   M2 Compliance LLC/FA

Quarterly Report   —   Form 10-Q
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML    241K 
 2: EX-10.1     Material Contract                                   HTML     56K 
 3: EX-10.2     Material Contract                                   HTML     59K 
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     22K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     22K 
 6: EX-32.1     Certification -- §906 - SOA'02                      HTML     17K 
 7: EX-32.2     Certification -- §906 - SOA'02                      HTML     17K 
14: R1          Document and Entity Information                     HTML     46K 
15: R2          Consolidated Balance Sheets (Unaudited)             HTML    109K 
16: R3          Consolidated Balance Sheets (Unaudited)             HTML     34K 
                (Parenthetical)                                                  
17: R4          Consolidated Statements of Operations (Unaudited)   HTML     71K 
18: R5          Consolidated Statements of Changes in               HTML     67K 
                Stockholders' Equity (Unaudited)                                 
19: R6          Consolidated Statements of Cash Flows (Unaudited)   HTML     98K 
20: R7          Organization and Basis of Presentation              HTML     31K 
21: R8          Short Term Debt - Related Parties                   HTML     18K 
22: R9          Stockholders' Equity                                HTML     23K 
23: R10         Warrants                                            HTML     24K 
24: R11         Options                                             HTML     28K 
25: R12         Other Receivables                                   HTML     21K 
26: R13         Contingencies                                       HTML     22K 
27: R14         Leases                                              HTML     26K 
28: R15         Segment Reporting                                   HTML     33K 
29: R16         Subsequent Events                                   HTML     20K 
30: R17         Organization and Basis of Presentation (Tables)     HTML     23K 
31: R18         Warrants (Tables)                                   HTML     24K 
32: R19         Options (Tables)                                    HTML     29K 
33: R20         Leases (Tables)                                     HTML     26K 
34: R21         Segment Reporting (Tables)                          HTML     30K 
35: R22         Organization and Basis of Presentation (Details     HTML     18K 
                Narrative)                                                       
36: R23         Organization and Basis of Presentation - Schedule   HTML     50K 
                of Basic and Dilutive Income (Loss) Per Share                    
                (Details)                                                        
37: R24         Short Term Debt - Related Parties (Details          HTML     41K 
                Narrative)                                                       
38: R25         Stockholders' Equity (Details Narrative)            HTML     38K 
39: R26         Warrants (Details Narrative)                        HTML     20K 
40: R27         Warrants - Schedule of Outstanding and Exercisable  HTML     52K 
                Warrants (Details)                                               
41: R28         Options (Details Narrative)                         HTML     37K 
42: R29         Options - Schedule of Estimate Fair Value of Stock  HTML     30K 
                Options (Details)                                                
43: R30         Options - Schedule of Stock Option Activity         HTML     71K 
                (Details)                                                        
44: R31         Other Receivables (Details Narrative)               HTML     26K 
45: R32         Contingencies (Details Narrative)                   HTML     24K 
46: R33         Leases (Details Narrative)                          HTML     23K 
47: R34         Leases - Schedule of Operating Leases (Details)     HTML     29K 
48: R35         Leases - Schedule of Future Minimum Payments for    HTML     39K 
                Operating Lease Liabilities (Details)                            
49: R36         Segment Reporting - Schedule of Business Interests  HTML     62K 
                Into Reportable Segments (Details)                               
50: R37         Subsequent Events (Details Narrative)               HTML     37K 
52: XML         IDEA XML File -- Filing Summary                      XML     85K 
51: EXCEL       IDEA Workbook of Financial Reports                  XLSX     48K 
 8: EX-101.INS  XBRL Instance -- trxd-20210331                       XML    511K 
10: EX-101.CAL  XBRL Calculations -- trxd-20210331_cal               XML    113K 
11: EX-101.DEF  XBRL Definitions -- trxd-20210331_def                XML    270K 
12: EX-101.LAB  XBRL Labels -- trxd-20210331_lab                     XML    706K 
13: EX-101.PRE  XBRL Presentations -- trxd-20210331_pre              XML    455K 
 9: EX-101.SCH  XBRL Schema -- trxd-20210331                         XSD    119K 
53: ZIP         XBRL Zipped Folder -- 0001493152-21-009653-xbrl      Zip     68K

‘EX-101.INS’   —   XBRL Instance — trxd-20210331

This Exhibit is an XBRL XML File.

                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.7a -->
<!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.com -->
<!-- Field: Doc-Info; Name: Source; Value: TRXD 20210331 10Q Q1 DFN.xfr; Date: 2021%2D04%2D26T18:00:35Z -->
<!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:TRXD="http://trxadegroup.com/20210331">
<link:schemaRef xlink:href="trxd-20210331.xsd" xlink:type="simple"/>
<xbrli:context id="AsOf2019-12-31">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2019-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2019-12-31_us-gaap_PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2019-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2019-12-31_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2019-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2019-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2019-12-31_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2019-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-03-31_custom_TrxadeIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis"> TRXD:TrxadeIncMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-03-31_custom_CommunitySpecialtyPharmacyLLCMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis"> TRXD:CommunitySpecialtyPharmacyLLCMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-03-31_us-gaap_AllOtherSegmentsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis"> us-gaap:AllOtherSegmentsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-03-31_custom_IntegraPharmaLLCMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis"> TRXD:IntegraPharmaLLCMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-03-31_custom_TrxadeIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis"> TRXD:TrxadeIncMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-03-31_custom_CommunitySpecialtyPharmacyLLCMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis"> TRXD:CommunitySpecialtyPharmacyLLCMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-03-31_us-gaap_AllOtherSegmentsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis"> us-gaap:AllOtherSegmentsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-03-31_custom_IntegraPharmaLLCMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis"> TRXD:IntegraPharmaLLCMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-01-31_us-gaap_SubsequentEventMember_custom_CompensatoryDamagesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis"> TRXD:CompensatoryDamagesMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-01-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-01-31_us-gaap_SubsequentEventMember_custom_PunitiveDamagesMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis"> TRXD:PunitiveDamagesMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-01-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-01to2021-03-31_custom_StockOptionPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> TRXD:StockOptionPlanMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-01-01 </xbrli:startDate>
<xbrli:endDate> 2021-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-01to2021-03-31_custom_TrxadeIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis"> TRXD:TrxadeIncMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-01-01 </xbrli:startDate>
<xbrli:endDate> 2021-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-03-31_custom_TrxadeIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis"> TRXD:TrxadeIncMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2021-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-01to2021-03-31_custom_CommunitySpecialtyPharmacyLLCMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis"> TRXD:CommunitySpecialtyPharmacyLLCMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-01-01 </xbrli:startDate>
<xbrli:endDate> 2021-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-03-31_custom_CommunitySpecialtyPharmacyLLCMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis"> TRXD:CommunitySpecialtyPharmacyLLCMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2021-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-01to2021-03-31_custom_IntegraPharmaLLCMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis"> TRXD:IntegraPharmaLLCMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-01-01 </xbrli:startDate>
<xbrli:endDate> 2021-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-03-31_custom_IntegraPharmaLLCMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis"> TRXD:IntegraPharmaLLCMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2021-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-01to2021-03-31_us-gaap_AllOtherSegmentsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis"> us-gaap:AllOtherSegmentsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-01-01 </xbrli:startDate>
<xbrli:endDate> 2021-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-03-31_us-gaap_AllOtherSegmentsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis"> us-gaap:AllOtherSegmentsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2021-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-01to2021-03-31_custom_TwoThousandAndNineteenAmendedAndRestatedTwoThousandAndNineteenEquityIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> TRXD:TwoThousandAndNineteenAmendedAndRestatedTwoThousandAndNineteenEquityIncentivePlanMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-01-01 </xbrli:startDate>
<xbrli:endDate> 2021-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-04-13to2020-04-14_us-gaap_SubsequentEventMember_custom_LegalCounselMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> TRXD:LegalCounselMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-04-13 </xbrli:startDate>
<xbrli:endDate> 2020-04-14 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-04-13to2020-04-14_us-gaap_SubsequentEventMember_custom_HowardADossMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> TRXD:HowardADossMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-04-13 </xbrli:startDate>
<xbrli:endDate> 2020-04-14 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-04-13to2020-04-14_us-gaap_SubsequentEventMember_custom_MrDonaldGFellDrPamelTenaertsAndMrMichaellPetersonMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> TRXD:MrDonaldGFellDrPamelTenaertsAndMrMichaellPetersonMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-04-13 </xbrli:startDate>
<xbrli:endDate> 2020-04-14 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-04-13to2020-04-14_custom_TwoThousandTwentyEquityCompensationAwardsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> TRXD:TwoThousandTwentyEquityCompensationAwardsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-04-13 </xbrli:startDate>
<xbrli:endDate> 2020-04-14 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-01to2021-03-31_custom_TwoThousandTwentyEquityCompensationAwardsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> TRXD:TwoThousandTwentyEquityCompensationAwardsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-01-01 </xbrli:startDate>
<xbrli:endDate> 2021-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-04-13to2020-04-14_custom_IndependentDirectorCompensationPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> TRXD:IndependentDirectorCompensationPlanMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-04-13 </xbrli:startDate>
<xbrli:endDate> 2020-04-14 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-01to2021-03-31_custom_IndependentDirectorCompensationPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> TRXD:IndependentDirectorCompensationPlanMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-01-01 </xbrli:startDate>
<xbrli:endDate> 2021-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-01to2021-03-31_custom_DamagesSoughtIsUnclearMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis"> TRXD:DamagesSoughtIsUnclearMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-01-01 </xbrli:startDate>
<xbrli:endDate> 2021-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-12-31">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-12-31_us-gaap_PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-12-31_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-04-22">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2021-04-22 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-07-01to2020-07-31_custom_IntegraMember_custom_StudebakerDefenseGroupLLCMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> TRXD:IntegraMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> TRXD:StudebakerDefenseGroupLLCMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-07-01 </xbrli:startDate>
<xbrli:endDate> 2020-07-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-08-13to2020-08-14_custom_IntegraMember_custom_StudebakerDefenseGroupLLCMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> TRXD:IntegraMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> TRXD:StudebakerDefenseGroupLLCMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-08-13 </xbrli:startDate>
<xbrli:endDate> 2020-08-14 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-12-01to2020-12-31_custom_IntegraMember_custom_StudebakerDefenseGroupLLCMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> TRXD:IntegraMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> TRXD:StudebakerDefenseGroupLLCMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-12-01 </xbrli:startDate>
<xbrli:endDate> 2020-12-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-08-01to2020-08-31_custom_IntegraMember_custom_SandwaveGroupDsnBhdMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> TRXD:IntegraMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> TRXD:SandwaveGroupDsnBhdMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-08-01 </xbrli:startDate>
<xbrli:endDate> 2020-08-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-02-01to2021-02-28_custom_IntegraMember_custom_SandwaveGroupDsnBhdMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis"> TRXD:IntegraMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> TRXD:SandwaveGroupDsnBhdMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-02-01 </xbrli:startDate>
<xbrli:endDate> 2021-02-28 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-12-31_custom_StockOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> TRXD:StockOptionsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-12-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-01to2021-03-31">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-01-01 </xbrli:startDate>
<xbrli:endDate> 2021-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-03-31">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2021-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-03-31">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-01to2021-03-31_us-gaap_PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-01-01 </xbrli:startDate>
<xbrli:endDate> 2021-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-03-31_us-gaap_PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-03-31_us-gaap_PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2021-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-03-31_us-gaap_PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:PreferredStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-01to2021-03-31_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-01-01 </xbrli:startDate>
<xbrli:endDate> 2021-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-03-31_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-03-31_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2021-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-03-31_us-gaap_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:CommonStockMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-01-01 </xbrli:startDate>
<xbrli:endDate> 2021-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2021-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:AdditionalPaidInCapitalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-01-01 </xbrli:startDate>
<xbrli:endDate> 2021-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2021-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-03-31_us-gaap_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:RetainedEarningsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2020-03-31">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2020-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2018-10-01to2018-10-31_custom_RelatedPartyPromissoryNoteMember_custom_CommunitySpecialtyPharmacyLLCMember_custom_NikulPanchalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> TRXD:RelatedPartyPromissoryNoteMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis"> TRXD:CommunitySpecialtyPharmacyLLCMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> TRXD:NikulPanchalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2018-10-01 </xbrli:startDate>
<xbrli:endDate> 2018-10-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2018-10-31_custom_RelatedPartyPromissoryNoteMember_custom_CommunitySpecialtyPharmacyLLCMember_custom_NikulPanchalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> TRXD:RelatedPartyPromissoryNoteMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis"> TRXD:CommunitySpecialtyPharmacyLLCMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> TRXD:NikulPanchalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2018-10-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2019-10-01to2019-10-31_custom_RelatedPartyPromissoryNoteMember_custom_CommunitySpecialtyPharmacyLLCMember_custom_NikulPanchalMember_us-gaap_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> TRXD:RelatedPartyPromissoryNoteMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis"> TRXD:CommunitySpecialtyPharmacyLLCMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> TRXD:NikulPanchalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2019-10-01 </xbrli:startDate>
<xbrli:endDate> 2019-10-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2019-10-31_custom_RelatedPartyPromissoryNoteMember_custom_CommunitySpecialtyPharmacyLLCMember_custom_NikulPanchalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis"> TRXD:RelatedPartyPromissoryNoteMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis"> TRXD:CommunitySpecialtyPharmacyLLCMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis"> TRXD:NikulPanchalMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2019-10-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-01to2021-03-31_us-gaap_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-01-01 </xbrli:startDate>
<xbrli:endDate> 2021-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2020-01-01to2020-03-31_us-gaap_WarrantMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis"> us-gaap:WarrantMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2020-01-01 </xbrli:startDate>
<xbrli:endDate> 2020-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-01to2021-03-31_srt_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MinimumMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-01-01 </xbrli:startDate>
<xbrli:endDate> 2021-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-01to2021-03-31_srt_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="srt:RangeAxis"> srt:MaximumMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-01-01 </xbrli:startDate>
<xbrli:endDate> 2021-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-01to2021-03-31_custom_StockOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> TRXD:StockOptionsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-01-01 </xbrli:startDate>
<xbrli:endDate> 2021-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-03-31_custom_StockOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis"> TRXD:StockOptionsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2021-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-01to2021-03-31_custom_LeaseOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> TRXD:LeaseOneMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-01-01 </xbrli:startDate>
<xbrli:endDate> 2021-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-03-31_custom_LeaseOneMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> TRXD:LeaseOneMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2021-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-01-01to2021-03-31_custom_LeaseTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> TRXD:LeaseTwoMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-01-01 </xbrli:startDate>
<xbrli:endDate> 2021-03-31 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-03-31_custom_LeaseTwoMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis"> TRXD:LeaseTwoMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2021-03-31 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-04-14to2021-04-15_custom_TwoThousandAndTwentyOneEquityCompensationAwardsMember_us-gaap_SubsequentEventMember_custom_MrDonaldGFellMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> TRXD:TwoThousandAndTwentyOneEquityCompensationAwardsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> TRXD:MrDonaldGFellMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-04-14 </xbrli:startDate>
<xbrli:endDate> 2021-04-15 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-04-14to2021-04-15_custom_TwoThousandAndTwentyOneEquityCompensationAwardsMember_us-gaap_SubsequentEventMember_custom_DrPamelaTenaertsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> TRXD:TwoThousandAndTwentyOneEquityCompensationAwardsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> TRXD:DrPamelaTenaertsMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-04-14 </xbrli:startDate>
<xbrli:endDate> 2021-04-15 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-04-14to2021-04-15_custom_TwoThousandAndTwentyOneEquityCompensationAwardsMember_us-gaap_SubsequentEventMember_custom_MrMichaelLPetersonMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> TRXD:TwoThousandAndTwentyOneEquityCompensationAwardsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis"> TRXD:MrMichaelLPetersonMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-04-14 </xbrli:startDate>
<xbrli:endDate> 2021-04-15 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="AsOf2021-04-15_custom_TwoThousandAndTwentyOneEquityCompensationAwardsMember_us-gaap_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> TRXD:TwoThousandAndTwentyOneEquityCompensationAwardsMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant> 2021-04-15 </xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="From2021-04-11to2021-04-15_us-gaap_SubsequentEventMember_custom_TwoThousandAndNineteenEquityIncentivePlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK"> 0001382574 </xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis"> us-gaap:SubsequentEventMember </xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis"> TRXD:TwoThousandAndNineteenEquityIncentivePlanMember </xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate> 2021-04-11 </xbrli:startDate>
<xbrli:endDate> 2021-04-15 </xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:unit id="USD">
<xbrli:measure> iso4217:USD </xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Shares">
<xbrli:measure> xbrli:shares </xbrli:measure>
</xbrli:unit>
<xbrli:unit id="USDPShares">
<xbrli:divide>
<xbrli:unitNumerator>
<xbrli:measure> iso4217:USD </xbrli:measure>
</xbrli:unitNumerator>
<xbrli:unitDenominator>
<xbrli:measure> xbrli:shares </xbrli:measure>
</xbrli:unitDenominator>
</xbrli:divide>
</xbrli:unit>
<xbrli:unit id="Percentage">
<xbrli:measure> xbrli:pure </xbrli:measure>
</xbrli:unit>
<xbrli:unit id="Integer">
<xbrli:measure> TRXD:Integer </xbrli:measure>
</xbrli:unit>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2020-12-31" unitRef="USDPShares" decimals="INF"> 0.00001 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2021-03-31" unitRef="USDPShares" decimals="INF"> 0.00001 </us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF"> 10000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-03-31" unitRef="Shares" decimals="INF"> 10000000 </us-gaap:PreferredStockSharesAuthorized>
<us-gaap:PreferredStockSharesIssued contextRef="AsOf2020-12-31" unitRef="Shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-03-31" unitRef="Shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2020-12-31" unitRef="Shares" xsi:nil="true"/>
<us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-03-31" unitRef="Shares" xsi:nil="true"/>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF"> 100000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-03-31" unitRef="Shares" decimals="INF"> 100000000 </us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2020-12-31" unitRef="USDPShares" decimals="INF"> 0.00001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2021-03-31" unitRef="USDPShares" decimals="INF"> 0.00001 </us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesIssued contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF"> 8093199 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="AsOf2021-03-31" unitRef="Shares" decimals="INF"> 8093199 </us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF"> 8093199 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-03-31" unitRef="Shares" decimals="INF"> 8093199 </us-gaap:CommonStockSharesOutstanding>
<us-gaap:NetIncomeLoss contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> -651519 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 180303 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2021-01-01to2021-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetIncomeLoss contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0"> -651519 </us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0"> 180303 </us-gaap:NetIncomeLoss>
<us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="AsOf2021-03-31" unitRef="Percentage" decimals="INF"> 1.00 </us-gaap:EquityMethodInvestmentOwnershipPercentage>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2021-01-01to2021-03-31_custom_TwoThousandAndNineteenAmendedAndRestatedTwoThousandAndNineteenEquityIncentivePlanMember" unitRef="Shares" decimals="INF"> 2000000 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-01-01to2020-03-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF"> 922219 </us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:DebtInstrumentConvertibleConversionPrice1 contextRef="AsOf2019-10-31_custom_RelatedPartyPromissoryNoteMember_custom_CommunitySpecialtyPharmacyLLCMember_custom_NikulPanchalMember" unitRef="USDPShares" decimals="INF"> 3.00 </us-gaap:DebtInstrumentConvertibleConversionPrice1>
<us-gaap:DebtConversionConvertedInstrumentSharesIssued1 contextRef="From2019-10-01to2019-10-31_custom_RelatedPartyPromissoryNoteMember_custom_CommunitySpecialtyPharmacyLLCMember_custom_NikulPanchalMember_us-gaap_SubsequentEventMember" unitRef="Shares" decimals="INF"> 25000 </us-gaap:DebtConversionConvertedInstrumentSharesIssued1>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2018-10-31_custom_RelatedPartyPromissoryNoteMember_custom_CommunitySpecialtyPharmacyLLCMember_custom_NikulPanchalMember" unitRef="Percentage" decimals="INF"> 0.10 </us-gaap:DebtInstrumentInterestRateStatedPercentage>
<us-gaap:DebtInstrumentMaturityDate contextRef="From2018-10-01to2018-10-31_custom_RelatedPartyPromissoryNoteMember_custom_CommunitySpecialtyPharmacyLLCMember_custom_NikulPanchalMember"> 2021-10-15 </us-gaap:DebtInstrumentMaturityDate>
<dei:EntityCommonStockSharesOutstanding contextRef="AsOf2021-04-22" unitRef="Shares" decimals="INF"> 8125362 </dei:EntityCommonStockSharesOutstanding>
<us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="From2019-10-01to2019-10-31_custom_RelatedPartyPromissoryNoteMember_custom_CommunitySpecialtyPharmacyLLCMember_custom_NikulPanchalMember_us-gaap_SubsequentEventMember" unitRef="USD" decimals="0"> 76500 </us-gaap:GainsLossesOnExtinguishmentOfDebt>
<us-gaap:DebtConversionConvertedInstrumentAmount1 contextRef="From2019-10-01to2019-10-31_custom_RelatedPartyPromissoryNoteMember_custom_CommunitySpecialtyPharmacyLLCMember_custom_NikulPanchalMember_us-gaap_SubsequentEventMember" unitRef="USD" decimals="0"> 75000 </us-gaap:DebtConversionConvertedInstrumentAmount1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2021-01-01to2021-03-31_custom_TwoThousandAndNineteenAmendedAndRestatedTwoThousandAndNineteenEquityIncentivePlanMember"> The Company's 2019 Amended and Restated 2019 Equity Incentive Plan provides for automatic increases in the number of shares available under such plan (currently 2,000,000 shares) on April 1st of each calendar year, beginning in 2021 and ending in 2029 (each a "Date of Determination"), in each case subject to the approval and determination of the administrator of the plan (the Board of Directors or Compensation Committee) on or prior to the applicable Date of Determination, equal to the lesser of (A) ten percent (10%) of the total shares of common stock of the Company outstanding on the last day of the immediately preceding fiscal year and (B) such smaller number of shares as determined by the administrator. </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2020-04-13to2020-04-14_us-gaap_SubsequentEventMember_custom_HowardADossMember"> Shares vest at the rate of ¼th of such shares on July 1 and October 1, 2020 and January 1 and April 1, 2021 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription contextRef="From2020-04-13to2020-04-14_custom_IndependentDirectorCompensationPlanMember"> which vest at the rate of ¼th of such shares on July 1 and October 1, 2020 and January 1 and April 1, 2021. </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardDescription>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2020-01-01to2020-03-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF"> 167 </us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2021-01-01to2021-03-31_custom_StockOptionsMember" unitRef="Shares" xsi:nil="true"/>
<us-gaap:LossContingencyDamagesSoughtValue contextRef="From2020-01-01to2020-01-31_us-gaap_SubsequentEventMember_custom_CompensatoryDamagesMember" unitRef="USD" decimals="0"> 425000 </us-gaap:LossContingencyDamagesSoughtValue>
<us-gaap:LossContingencyDamagesSoughtValue contextRef="From2020-01-01to2020-01-31_us-gaap_SubsequentEventMember_custom_PunitiveDamagesMember" unitRef="USD" decimals="0"> 1275000 </us-gaap:LossContingencyDamagesSoughtValue>
<us-gaap:LossContingencyDamagesSoughtValue contextRef="From2021-01-01to2021-03-31_custom_DamagesSoughtIsUnclearMember" unitRef="USD" decimals="0"> 425000 </us-gaap:LossContingencyDamagesSoughtValue>
<us-gaap:LossContingencyDamagesSoughtValue contextRef="From2020-12-01to2020-12-31_custom_IntegraMember_custom_StudebakerDefenseGroupLLCMember" unitRef="USD" decimals="0"> 500000 </us-gaap:LossContingencyDamagesSoughtValue>
<us-gaap:LossContingencyDamagesSoughtValue contextRef="From2021-02-01to2021-02-28_custom_IntegraMember_custom_SandwaveGroupDsnBhdMember" unitRef="USD" decimals="0"> 581250 </us-gaap:LossContingencyDamagesSoughtValue>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromStockOptionsExercised contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 501 </us-gaap:ProceedsFromStockOptionsExercised>
<us-gaap:ShareBasedCompensation contextRef="From2021-01-01to2021-03-31_custom_TwoThousandTwentyEquityCompensationAwardsMember" unitRef="USD" decimals="0"> 53550 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="From2021-01-01to2021-03-31_custom_IndependentDirectorCompensationPlanMember" unitRef="USD" decimals="0"> 82500 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> 75738 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 61997 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="From2021-01-01to2021-03-31_us-gaap_WarrantMember" unitRef="USD" decimals="0"> 0 </us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="From2020-01-01to2020-03-31_us-gaap_WarrantMember" unitRef="USD" decimals="0"> 79089 </us-gaap:ShareBasedCompensation>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 5994424 </us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2020-04-13to2020-04-14_us-gaap_SubsequentEventMember_custom_LegalCounselMember" unitRef="Shares" decimals="INF"> 5000 </us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2020-04-13to2020-04-14_us-gaap_SubsequentEventMember_custom_HowardADossMember" unitRef="Shares" decimals="INF"> 12500 </us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross contextRef="From2020-04-13to2020-04-14_us-gaap_SubsequentEventMember_custom_MrDonaldGFellDrPamelTenaertsAndMrMichaellPetersonMember" unitRef="Shares" decimals="INF"> 8987 </us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2020-04-13to2020-04-14_custom_TwoThousandTwentyEquityCompensationAwardsMember" unitRef="USD" decimals="0"> 107100 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross contextRef="From2020-04-13to2020-04-14_custom_IndependentDirectorCompensationPlanMember" unitRef="USD" decimals="0"> 165000 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
<us-gaap:StockholdersEquity contextRef="AsOf2019-12-31" unitRef="USD" decimals="0"> 4140217 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0"> 65 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0"> 12535655 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2019-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0"> -8395503 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 8679158 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0"> 81 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0"> 19610631 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0"> -10931554 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 8201624 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0"> 81 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0"> 75 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0"> 19784616 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0"> 17852422 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0"> -11583073 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0"> -8215200 </us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="AsOf2020-03-31" unitRef="USD" decimals="0"> 9637297 </us-gaap:StockholdersEquity>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> 75738 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 61997 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2021-01-01to2021-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2020-01-01to2020-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0"> 75738 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0"> 61997 </us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 5919578 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 5209280 </us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 805043 </us-gaap:AccountsReceivableNetCurrent>
<us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 1936850 </us-gaap:AccountsReceivableNetCurrent>
<us-gaap:InventoryNet contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 1257754 </us-gaap:InventoryNet>
<us-gaap:InventoryNet contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 470122 </us-gaap:InventoryNet>
<us-gaap:PrepaidExpenseCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 151248 </us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 457738 </us-gaap:PrepaidExpenseCurrent>
<us-gaap:AssetsCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 9221298 </us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 9155240 </us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 162397 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 160647 </us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 21636 </us-gaap:DepositsAssetsNoncurrent>
<us-gaap:DepositsAssetsNoncurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 21636 </us-gaap:DepositsAssetsNoncurrent>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 387371 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 355693 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-03-31_custom_LeaseOneMember" unitRef="USD" decimals="0"> 534140 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-03-31_custom_LeaseTwoMember" unitRef="USD" decimals="0"> 313301 </us-gaap:OperatingLeaseRightOfUseAsset>
<us-gaap:Assets contextRef="AsOf2020-03-31_custom_TrxadeIncMember" unitRef="USD" decimals="0"> 2055429 </us-gaap:Assets>
<us-gaap:Assets contextRef="AsOf2020-03-31_custom_CommunitySpecialtyPharmacyLLCMember" unitRef="USD" decimals="0"> 280514 </us-gaap:Assets>
<us-gaap:Assets contextRef="AsOf2020-03-31_us-gaap_AllOtherSegmentsMember" unitRef="USD" decimals="0"> 7320791 </us-gaap:Assets>
<us-gaap:Assets contextRef="AsOf2020-03-31_custom_IntegraPharmaLLCMember" unitRef="USD" decimals="0"> 1817170 </us-gaap:Assets>
<us-gaap:Assets contextRef="AsOf2021-03-31_custom_TrxadeIncMember" unitRef="USD" decimals="0"> 2053494 </us-gaap:Assets>
<us-gaap:Assets contextRef="AsOf2021-03-31_custom_CommunitySpecialtyPharmacyLLCMember" unitRef="USD" decimals="0"> -405348 </us-gaap:Assets>
<us-gaap:Assets contextRef="AsOf2021-03-31_custom_IntegraPharmaLLCMember" unitRef="USD" decimals="0"> 3111536 </us-gaap:Assets>
<us-gaap:Assets contextRef="AsOf2021-03-31_us-gaap_AllOtherSegmentsMember" unitRef="USD" decimals="0"> 4933534 </us-gaap:Assets>
<us-gaap:Assets contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 9792702 </us-gaap:Assets>
<us-gaap:Assets contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 9693216 </us-gaap:Assets>
<us-gaap:Assets contextRef="AsOf2020-03-31" unitRef="USD" decimals="0"> 11473904 </us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 256829 </us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 366471 </us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 219256 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 519179 </us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 131153 </us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 117030 </us-gaap:OperatingLeaseLiabilityCurrent>
<us-gaap:LiabilitiesCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 842238 </us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 1237680 </us-gaap:LiabilitiesCurrent>
<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 271306 </us-gaap:OperatingLeaseLiabilityNoncurrent>
<us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 253912 </us-gaap:OperatingLeaseLiabilityNoncurrent>
<us-gaap:Liabilities contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 1113544 </us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 1491592 </us-gaap:Liabilities>
<us-gaap:PreferredStockValue contextRef="AsOf2020-12-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="AsOf2021-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommonStockValue contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 81 </us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 81 </us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 19610631 </us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 19784616 </us-gaap:AdditionalPaidInCapital>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> -10931554 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> -11583073 </us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 9792702 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 9693216 </us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 1087675 </us-gaap:AccountsAndOtherReceivablesNetCurrent>
<us-gaap:AccountsAndOtherReceivablesNetCurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 1081250 </us-gaap:AccountsAndOtherReceivablesNetCurrent>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2020-01-01to2020-03-31_custom_TrxadeIncMember" unitRef="USD" decimals="0"> 1519907 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2020-01-01to2020-03-31_custom_CommunitySpecialtyPharmacyLLCMember" unitRef="USD" decimals="0"> 432929 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2020-01-01to2020-03-31_us-gaap_AllOtherSegmentsMember" unitRef="USD" decimals="0"> 5468 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2020-01-01to2020-03-31_custom_IntegraPharmaLLCMember" unitRef="USD" decimals="0"> 245016 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2021-01-01to2021-03-31_custom_TrxadeIncMember" unitRef="USD" decimals="0"> 1236650 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2021-01-01to2021-03-31_custom_CommunitySpecialtyPharmacyLLCMember" unitRef="USD" decimals="0"> 397896 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2021-01-01to2021-03-31_custom_IntegraPharmaLLCMember" unitRef="USD" decimals="0"> 1402586 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2021-01-01to2021-03-31_us-gaap_AllOtherSegmentsMember" unitRef="USD" decimals="0"> 16103 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> 3053235 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 2203320 </us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
<us-gaap:CostOfGoodsAndServicesSold contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> 1669924 </us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:CostOfGoodsAndServicesSold contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 563184 </us-gaap:CostOfGoodsAndServicesSold>
<us-gaap:GrossProfit contextRef="From2020-01-01to2020-03-31_custom_TrxadeIncMember" unitRef="USD" decimals="0"> 1519907 </us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="From2020-01-01to2020-03-31_custom_CommunitySpecialtyPharmacyLLCMember" unitRef="USD" decimals="0"> 36108 </us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="From2020-01-01to2020-03-31_us-gaap_AllOtherSegmentsMember" unitRef="USD" decimals="0"> 5468 </us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="From2020-01-01to2020-03-31_custom_IntegraPharmaLLCMember" unitRef="USD" decimals="0"> 78653 </us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="From2021-01-01to2021-03-31_custom_TrxadeIncMember" unitRef="USD" decimals="0"> 1236650 </us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="From2021-01-01to2021-03-31_custom_CommunitySpecialtyPharmacyLLCMember" unitRef="USD" decimals="0"> 36089 </us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="From2021-01-01to2021-03-31_custom_IntegraPharmaLLCMember" unitRef="USD" decimals="0"> 94563 </us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="From2021-01-01to2021-03-31_us-gaap_AllOtherSegmentsMember" unitRef="USD" decimals="0"> 16009 </us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> 1383311 </us-gaap:GrossProfit>
<us-gaap:GrossProfit contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 1640136 </us-gaap:GrossProfit>
<us-gaap:GeneralAndAdministrativeExpense contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> 2027566 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:GeneralAndAdministrativeExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 1451909 </us-gaap:GeneralAndAdministrativeExpense>
<us-gaap:OperatingIncomeLoss contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> -644255 </us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 188227 </us-gaap:OperatingIncomeLoss>
<TRXD:StockIssuedDuringPeriodValueWarrantsExercisedForCash contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 1352 </TRXD:StockIssuedDuringPeriodValueWarrantsExercisedForCash>
<TRXD:StockIssuedDuringPeriodValueWarrantsExercisedForCash contextRef="From2020-01-01to2020-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true"/>
<TRXD:StockIssuedDuringPeriodValueWarrantsExercisedForCash contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<TRXD:StockIssuedDuringPeriodValueWarrantsExercisedForCash contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0"> 1352 </TRXD:StockIssuedDuringPeriodValueWarrantsExercisedForCash>
<TRXD:StockIssuedDuringPeriodValueWarrantsExercisedForCash contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 820586 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2020-01-01to2020-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0"> 820586 </us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> 98247 </us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2021-01-01to2021-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2021-01-01to2021-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0"> 98247 </us-gaap:StockIssuedDuringPeriodValueIssuedForServices>
<us-gaap:StockIssuedDuringPeriodValueIssuedForServices contextRef="From2021-01-01to2021-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 501 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-01-01to2020-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0"> 501 </us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromWarrantExercises contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProceedsFromWarrantExercises contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 1352 </us-gaap:ProceedsFromWarrantExercises>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-01-01to2021-03-31_custom_StockOptionPlanMember" unitRef="Shares" decimals="INF"> 2333333 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-01-01to2021-03-31" unitRef="Shares" decimals="INF"> 20000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-01-01to2021-03-31_custom_StockOptionsMember" unitRef="Shares" decimals="INF"> 20000 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2021-04-11to2021-04-15_us-gaap_SubsequentEventMember_custom_TwoThousandAndNineteenEquityIncentivePlanMember" unitRef="Shares" decimals="INF"> 17500 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2021-01-01to2021-03-31" unitRef="USDPShares" decimals="INF"> 6.55 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2021-01-01to2021-03-31_custom_StockOptionsMember" unitRef="USDPShares" decimals="INF"> 6.55 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2021-04-11to2021-04-15_us-gaap_SubsequentEventMember_custom_TwoThousandAndNineteenEquityIncentivePlanMember" unitRef="USDPShares" decimals="INF"> 4.76 </us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2021-01-01to2021-03-31_custom_StockOptionsMember"> P5Y3M29D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2021-01-01to2021-03-31"> P4Y </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:SharesIssuedPricePerShare contextRef="AsOf2021-04-15_custom_TwoThousandAndTwentyOneEquityCompensationAwardsMember_us-gaap_SubsequentEventMember" unitRef="USDPShares" decimals="INF"> 5.13 </us-gaap:SharesIssuedPricePerShare>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted contextRef="From2021-01-01to2021-03-31" unitRef="Shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2020-12-31" unitRef="Shares" decimals="INF"> 82751 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber contextRef="AsOf2021-03-31" unitRef="Shares" decimals="INF"> 82751 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2021-01-01to2021-03-31" unitRef="Shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsForfeituresAndExpirations contextRef="From2021-01-01to2021-03-31" unitRef="Shares" xsi:nil="true"/>
<TRXD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-12-31" unitRef="USDPShares" decimals="INF"> 1.33 </TRXD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
<TRXD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-03-31" unitRef="USDPShares" decimals="INF"> 1.33 </TRXD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice>
<TRXD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2021-01-01to2021-03-31" unitRef="USDPShares" xsi:nil="true"/>
<TRXD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExpiredForfeitedInPeriodWeightedAverageExercisePrice contextRef="From2021-01-01to2021-03-31" unitRef="USDPShares" xsi:nil="true"/>
<TRXD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2021-01-01to2021-03-31" unitRef="USDPShares" xsi:nil="true"/>
<TRXD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableWeightedAverageExercisePrice contextRef="AsOf2021-03-31" unitRef="USDPShares" decimals="INF"> 1.81 </TRXD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableWeightedAverageExercisePrice>
<TRXD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableNumber contextRef="AsOf2021-03-31" unitRef="Shares" decimals="INF"> 60223 </TRXD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityExercisableNumber>
<TRXD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 352951 </TRXD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue>
<TRXD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 349157 </TRXD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionsEquityInstrumentOutstandingIntrinsicValue>
<TRXD:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityExercisableIntrinsicValue1 contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 232462 </TRXD:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityExercisableIntrinsicValue1>
<TRXD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning contextRef="From2021-01-01to2021-03-31"> P2Y8M23D </TRXD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermBeginning>
<TRXD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageRemainingContractualTerm contextRef="From2021-01-01to2021-03-31"> P0Y </TRXD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantedInPeriodWeightedAverageRemainingContractualTerm>
<TRXD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding contextRef="From2021-01-01to2021-03-31"> P2Y5M23D </TRXD:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTermEnding>
<TRXD:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2021-01-01to2021-03-31"> P1Y4M2D </TRXD:SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2021-01-01to2021-03-31_custom_StockOptionsMember" unitRef="Shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="From2021-01-01to2021-03-31_custom_StockOptionsMember" unitRef="Shares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2021-01-01to2021-03-31" unitRef="Percentage" decimals="INF"> 0.00 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2021-01-01to2021-03-31_srt_MinimumMember" unitRef="Percentage" decimals="INF"> 1.06 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="From2021-01-01to2021-03-31_srt_MaximumMember" unitRef="Percentage" decimals="INF"> 2.15 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="From2021-01-01to2021-03-31" unitRef="Percentage" decimals="INF"> 0.0025 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2021-01-01to2021-03-31"> P5Y </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2020-12-31_custom_StockOptionsMember" unitRef="Shares" decimals="INF"> 282167 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2021-03-31_custom_StockOptionsMember" unitRef="Shares" decimals="INF"> 304867 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2020-12-31_custom_StockOptionsMember" unitRef="Shares" decimals="INF"> 425817 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-03-31_custom_StockOptionsMember" unitRef="Shares" decimals="INF"> 445817 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice contextRef="From2021-01-01to2021-03-31_custom_StockOptionsMember" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2021-01-01to2021-03-31_custom_StockOptionsMember" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2020-12-31_custom_StockOptionsMember" unitRef="USDPShares" decimals="INF"> 4.52 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2021-03-31_custom_StockOptionsMember" unitRef="USDPShares" decimals="INF"> 4.44 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2020-12-31_custom_StockOptionsMember" unitRef="USDPShares" decimals="INF"> 4.44 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2021-03-31_custom_StockOptionsMember" unitRef="USDPShares" decimals="INF"> 4.53 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2021-01-01to2021-03-31_custom_StockOptionsMember" unitRef="USDPShares" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2020-12-31_custom_StockOptionsMember" unitRef="USD" decimals="0"> 384226 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2021-03-31_custom_StockOptionsMember" unitRef="USD" decimals="0"> 421737 </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2020-12-31_custom_StockOptionsMember" unitRef="USD" decimals="0"> 597322 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2021-03-31_custom_StockOptionsMember" unitRef="USD" decimals="0"> 586080 </us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="From2021-01-01to2021-03-31_custom_StockOptionsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2021-01-01to2021-03-31_custom_StockOptionsMember"> P4Y6M21D </us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
<TRXD:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted contextRef="From2021-01-01to2021-03-31_custom_StockOptionsMember"> P4Y10M6D </TRXD:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermGranted>
<TRXD:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermForfeitures contextRef="From2021-01-01to2021-03-31_custom_StockOptionsMember"> P0Y </TRXD:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermForfeitures>
<TRXD:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm contextRef="From2021-01-01to2021-03-31_custom_StockOptionsMember"> P5Y26D </TRXD:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm>
<TRXD:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm contextRef="From2021-01-01to2021-03-31_custom_StockOptionsMember"> P4Y6M7D </TRXD:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm>
<TRXD:DownPayment contextRef="From2020-07-01to2020-07-31_custom_IntegraMember_custom_StudebakerDefenseGroupLLCMember" unitRef="USD" decimals="0"> 500000 </TRXD:DownPayment>
<TRXD:DownPayment contextRef="From2020-08-01to2020-08-31_custom_IntegraMember_custom_SandwaveGroupDsnBhdMember" unitRef="USD" decimals="0"> 581250 </TRXD:DownPayment>
<TRXD:NumberOfNitrileGlovesDelivered contextRef="From2020-08-13to2020-08-14_custom_IntegraMember_custom_StudebakerDefenseGroupLLCMember" unitRef="Integer" decimals="INF"> 180000 </TRXD:NumberOfNitrileGlovesDelivered>
<TRXD:NumberOfNitrileGlovesDelivered contextRef="From2020-08-01to2020-08-31_custom_IntegraMember_custom_SandwaveGroupDsnBhdMember" unitRef="Integer" decimals="INF"> 150000 </TRXD:NumberOfNitrileGlovesDelivered>
<TRXD:OperatingLeaseRenewalTerm contextRef="From2021-01-01to2021-03-31_custom_LeaseOneMember"> January 2021 to December 2024 </TRXD:OperatingLeaseRenewalTerm>
<TRXD:OperatingLeaseRenewalTerm contextRef="From2021-01-01to2021-03-31_custom_LeaseTwoMember"> November 2023 to November 2028 </TRXD:OperatingLeaseRenewalTerm>
<us-gaap:LesseeOperatingLeaseDiscountRate contextRef="AsOf2021-03-31_custom_LeaseOneMember" unitRef="Percentage" decimals="INF"> 0.10 </us-gaap:LesseeOperatingLeaseDiscountRate>
<us-gaap:LesseeOperatingLeaseDiscountRate contextRef="AsOf2021-03-31_custom_LeaseTwoMember" unitRef="Percentage" decimals="INF"> 0.10 </us-gaap:LesseeOperatingLeaseDiscountRate>
<us-gaap:OperatingLeaseLiability contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 370942 </us-gaap:OperatingLeaseLiability>
<us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 129253 </us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 500195 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 147046 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 54052 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 52478 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 50949 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 49452 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
<us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 146218 </us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
<us-gaap:ProfitLoss contextRef="From2020-01-01to2020-03-31_custom_TrxadeIncMember" unitRef="USD" decimals="0"> 972993 </us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="From2020-01-01to2020-03-31_custom_CommunitySpecialtyPharmacyLLCMember" unitRef="USD" decimals="0"> -41245 </us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="From2020-01-01to2020-03-31_us-gaap_AllOtherSegmentsMember" unitRef="USD" decimals="0"> -722562 </us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="From2020-01-01to2020-03-31_custom_IntegraPharmaLLCMember" unitRef="USD" decimals="0"> -28883 </us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="From2021-01-01to2021-03-31_custom_TrxadeIncMember" unitRef="USD" decimals="0"> 512293 </us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="From2021-01-01to2021-03-31_custom_CommunitySpecialtyPharmacyLLCMember" unitRef="USD" decimals="0"> -31251 </us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="From2021-01-01to2021-03-31_custom_IntegraPharmaLLCMember" unitRef="USD" decimals="0"> -32446 </us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="From2021-01-01to2021-03-31_us-gaap_AllOtherSegmentsMember" unitRef="USD" decimals="0"> -1100115 </us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> -651519 </us-gaap:ProfitLoss>
<us-gaap:ProfitLoss contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 180303 </us-gaap:ProfitLoss>
<us-gaap:LossContingencyDisclosures contextRef="From2021-01-01to2021-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 7 – CONTINGENCIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In January 2020, we became aware of a complaint filed by Jitendra Jain, Manish Arora, Scariy Kumaramangalam, Harsh Datta and Balvant Arora (collectively, plaintiffs), against our wholly-owned subsidiary, Trxade, Inc. and our Chief Executive Officer, Suren Ajjarapu as well as certain unrelated persons, Annapurna Gundlapalli, Gajan Mahendiran and Nexgen Memantine (collectively, defendants), in the Circuit Court of Madison County, Alabama (Case:47-CV-2019-902216.00). The complaint alleged causes of actions against the defendants including fraud in the inducement, relating to certain investments alleged to have been made by plaintiffs in Nexgen Memantine, breach of fiduciary duty, conversion and voidable transactions. The complaint related to certain investments alleged made by the plaintiffs in Nexgen Memantine and certain alleged fraudulent transfers of assets and funds alleged to have been taken by the defendants which are unrelated to the Company. The complaint sought $425,000 in compensatory damages and $1,275,000 in punitive damages. The Company and Mr. Ajjarapu denied in their entirety the plaintiffs’ allegations and filed a motion to dismiss the plaintiffs’ claims against the Company and Mr. Ajjarapu, which motion was granted in May 2020, due to the plaintiffs not being able to establish personal jurisdiction over the defendants, which motion was successful as to all defendants. The Company and Mr. Ajjarapu further refute any connections for the purpose of the suit to the other named defendants. To the Company’s and Mr. Ajjarapu’s knowledge, the complaint had no merit whatsoever. The final date for the plaintiffs to appeal the ruling to dismiss the lawsuit passed in August 2020, and there was no appeal. As such, the ruling is final.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">However, in September 2020, the plaintiffs filed a similar complaint (alleging substantially similar facts) in the United States District Court for the Middle District of Florida, Tampa Division (Case 8:20-cv-02263), against the same defendants but adding Westminster Pharmaceuticals, LLC, our former wholly-owned subsidiary (“<u>Westminster</u>”), and raising claims for alleged fraud under Section 10(b) and Rule 10b-5 of the Exchange Act; joint and several liability under 15 U.S.C. Code 78t (against Trxade, Inc.); fraudulent transactions of securities under the Florida Securities Act (against all of the defendants except Trxade); and sale of unregistered securities under the Florida Securities Act (against all of the defendants except Trxade). The total amount of damages sought is unclear, but is thought to be in excess of $425,000. To the Company’s and Mr. Ajjarapu’s knowledge, the complaint has no merit whatsoever and each of the Company and Mr. Ajjarapu intend to defend themselves and oppose the relief sought in the complaint. The Company is not currently accused of any direct misconduct; instead, the Company is alleged to be liable for the acts of certain or all of the other defendants. The Company would likely only incur liability if some or all of the other defendants were found liable to plaintiffs and the Company is found to be jointly and severally liable for the actions of such other defendant or defendants. The lawsuit claims approximately $450,000 in damages; however, based on facts currently known, the Company assesses the likelihood of any material loss as remote.</p>
</us-gaap:LossContingencyDisclosures>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2021-01-01to2021-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table summarizes the assumptions used to estimate the fair value of the stock options granted during the quarter ended March 31, 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%; text-align: justify"><font style="font-size: 10pt">Expected dividend yield</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right"><font style="font-size: 10pt">0</font></td> <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Weighted-average expected volatility</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">106-215 </font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Weighted-average risk-free interest rate</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">0.25</font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Expected life of options</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">5 years</font></td> <td> </td></tr> </table>
</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2021-01-01to2021-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents stock option activity for the three-month period ended March 31, 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Number Outstanding</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted Average Exercise Price</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Contractual Life in Years</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Intrinsic Value</b></font></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%"><font style="font-size: 10pt">Options Outstanding as of December 31, 2020</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">425,817</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">4.44</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">5.33</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">597,322</font></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Options Exercisable as of December 31, 2020</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">282,167</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">4.52</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">4.56</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">384,226</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Options granted</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">20,000</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">6.55</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">4.85</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Options forfeited</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Options expired</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Options exercised</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Options Outstanding as of March 31, 2021</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">445,817</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">4.53</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">5.07</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">586,080</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Options Exercisable as of March 31, 2021</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">304,867</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">4.44</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">4.52</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">421,737</font></td> <td> </td></tr> </table>
</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:LeaseCostTableTextBlock contextRef="From2021-01-01to2021-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table outlines the details:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: justify"><font style="font-size: 10pt">Lease 1</font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: justify"><font style="font-size: 10pt">Lease 2</font></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Initial Lease Term</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">December 2017 to December 2021</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">November 2018 to November 2023</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Renewal Term</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">January 2021 to December 2024</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">November 2023 to November 2028</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Initial Recognition of right-of-use assets at January 1, 2019</font></td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">534,140</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">313,301</font></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Incremental Borrowing Rate</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">10</font></td> <td><font style="font-size: 10pt">%</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">10</font></td> <td><font style="font-size: 10pt">%</font></td></tr> </table>
</us-gaap:LeaseCostTableTextBlock>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 79089 </us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2020-01-01to2020-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0"> 79089 </us-gaap:AdjustmentsToAdditionalPaidInCapitalOther>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<TRXD:StockIssuedDuringPeriodValueReverseStockSplits contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true"/>
<TRXD:StockIssuedDuringPeriodValueReverseStockSplits contextRef="From2020-01-01to2020-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true"/>
<TRXD:StockIssuedDuringPeriodValueReverseStockSplits contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true"/>
<TRXD:StockIssuedDuringPeriodValueReverseStockSplits contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true"/>
<TRXD:StockIssuedDuringPeriodValueReverseStockSplits contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:LesseeOperatingLeaseDescription contextRef="From2021-01-01to2021-03-31_custom_LeaseOneMember"> December 2017 to December 2021 </us-gaap:LesseeOperatingLeaseDescription>
<us-gaap:LesseeOperatingLeaseDescription contextRef="From2021-01-01to2021-03-31_custom_LeaseTwoMember"> November 2018 to November 2023 </us-gaap:LesseeOperatingLeaseDescription>
<us-gaap:LossContingencyDamagesPaidValue contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> 450000 </us-gaap:LossContingencyDamagesPaidValue>
<us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 10000 </us-gaap:ContractWithCustomerLiabilityCurrent>
<us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 10000 </us-gaap:ContractWithCustomerLiabilityCurrent>
<us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2021-01-01to2021-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 8 – LEASES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company elected the practical expedient under Accounting Standards Update (ASU) 2018-11 “<u>Leases: Targeted Improvements</u>” which allows the Company to apply the transition provision for Topic 842 at the Company’s adoption date instead of at the earliest comparative period presented in the financial statements. Therefore, the Company recognized and measured leases existing at January 1, 2019, but without retrospective application. In addition, the Company elected the optional practical expedient permitted under the transition guidance which allows the Company to carry forward the historical accounting treatment for existing leases upon adoption. No impact was recorded to the beginning retained earnings for Topic 842. The Company has two operating leases for corporate offices. The following table outlines the details:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: justify"><font style="font-size: 10pt">Lease 1</font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: justify"><font style="font-size: 10pt">Lease 2</font></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Initial Lease Term</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">December 2017 to December 2021</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">November 2018 to November 2023</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Renewal Term</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">January 2021 to December 2024</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">November 2023 to November 2028</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 62%"><font style="font-size: 10pt">Initial Recognition of right-of-use assets at January 1, 2019</font></td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">534,140</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 16%; text-align: right"><font style="font-size: 10pt">313,301</font></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Incremental Borrowing Rate</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">10</font></td> <td><font style="font-size: 10pt">%</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">10</font></td> <td><font style="font-size: 10pt">%</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company decided not to renew the corporate office lease (Lease 1) on January 2021; however, the parties subsequently negotiated a one-year lease at the same location. The Company determined that the decision to not renew Lease 1 changed the corresponding lease term which required remeasurement of the lease liability resulting in the reduction of the right-of-use asset and the associated lease liability by $384,110. The reassessment of the lease term did not change the existing classification and the lease is still classified as an operating lease.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below reconciles the fixed component of the undiscounted cash flows for each of the first five years and the total remaining years to the operating lease liabilities recorded in the Consolidated Balance Sheet as of March 31, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt"><b>Amounts due within twelve months of March 31</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%"><font style="font-size: 10pt">2021</font></td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 15%; text-align: right"><font style="font-size: 10pt">146,218</font></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">2022</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">49,452</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">2023</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">50,949</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">2024</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">52,478</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">2025</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">54,052</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Thereafter</font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">147,046</font></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Total minimum lease payments</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">500,195</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less: effect of discounting</font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(129,253</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Present value of future minimum lease payments</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">370,942</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less: current obligations under leases</font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">117,030</font></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Long-term lease obligations</font></td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">253,912</font></td> <td style="padding-bottom: 2.5pt"> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended March 31, 2021 and 2020, amortization of Right of Use Assets was $31,678 and $23,635, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three months ended March 31, 2021 and 2020, amortization of Lease Liability was $31,517 and $20,974, respectively.</p>
</us-gaap:LesseeOperatingLeasesTextBlock>
<us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2021-01-01to2021-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The table below reconciles the fixed component of the undiscounted cash flows for each of the first five years and the total remaining years to the operating lease liabilities recorded in the Consolidated Balance Sheet as of March 31, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt"><b>Amounts due within twelve months of March 31</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="text-align: right"> </td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%"><font style="font-size: 10pt">2021</font></td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 15%; text-align: right"><font style="font-size: 10pt">146,218</font></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">2022</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">49,452</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">2023</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">50,949</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">2024</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">52,478</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">2025</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">54,052</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Thereafter</font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">147,046</font></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Total minimum lease payments</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">500,195</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less: effect of discounting</font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(129,253</font></td> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Present value of future minimum lease payments</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">370,942</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less: current obligations under leases</font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">117,030</font></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Long-term lease obligations</font></td> <td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td> <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">253,912</font></td> <td style="padding-bottom: 2.5pt"> </td></tr> </table>
</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2021-01-01to2021-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 5 – OPTIONS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company maintains stock option plans under which certain employees are awarded option grants based on a combination of performance and tenure. The stock option plans provide for the grant of up to 2,333,333 shares, and the Company’s 2019 Amended and Restated 2019 Equity Incentive Plan provides for automatic increases in the number of shares available under such plan (currently 2,000,000 shares) on April 1<sup>st</sup> of each calendar year, beginning in 2021 and ending in 2029 (each a “<u>Date of Determination</u>”), in each case subject to the approval and determination of the administrator of the plan (the Board of Directors or Compensation Committee) on or prior to the applicable Date of Determination, equal to the lesser of (A) ten percent (10%) of the total shares of common stock of the Company outstanding on the last day of the immediately preceding fiscal year and (B) such smaller number of shares as determined by the administrator. The administrator did not approve an increase in the number of shares covered under the plan as of April 1, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three-month period ended March 31, 2021, options to purchase 20,000 shares were granted, none were forfeited and none expired. The options granted during the period vest over a four-year period, the exercise price was $6.55 per share and the options have a term of 5 years.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the Black-Scholes option pricing model to estimate the fair value of stock-based awards on the date of the grant. The following table summarizes the assumptions used to estimate the fair value of the stock options granted during the quarter ended March 31, 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 82%; text-align: justify"><font style="font-size: 10pt">Expected dividend yield</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 15%; text-align: right"><font style="font-size: 10pt">0</font></td> <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Weighted-average expected volatility</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">106-215 </font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Weighted-average risk-free interest rate</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">0.25</font></td> <td><font style="font-size: 10pt">%</font></td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Expected life of options</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">5 years</font></td> <td> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Total compensation cost related to stock options granted was $75,738 and $61,997 for the three months ended March 31, 2021 and 2020, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table represents stock option activity for the three-month period ended March 31, 2021:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Number Outstanding</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted Average Exercise Price</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Contractual Life in Years</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Intrinsic Value</b></font></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%"><font style="font-size: 10pt">Options Outstanding as of December 31, 2020</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">425,817</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">4.44</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">5.33</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">597,322</font></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Options Exercisable as of December 31, 2020</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">282,167</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">4.52</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">4.56</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">384,226</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Options granted</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">20,000</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">6.55</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">4.85</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Options forfeited</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Options expired</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Options exercised</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Options Outstanding as of March 31, 2021</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">445,817</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">4.53</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">5.07</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">586,080</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Options Exercisable as of March 31, 2021</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">304,867</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">4.44</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">4.52</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">421,737</font></td> <td> </td></tr> </table>
</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true"/>
<us-gaap:SharesOutstanding contextRef="AsOf2019-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF"> 6539415 </us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="AsOf2020-12-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true"/>
<us-gaap:SharesOutstanding contextRef="AsOf2020-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF"> 8093199 </us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="AsOf2021-03-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true"/>
<us-gaap:SharesOutstanding contextRef="AsOf2020-03-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true"/>
<us-gaap:SharesOutstanding contextRef="AsOf2021-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF"> 8093199 </us-gaap:SharesOutstanding>
<us-gaap:SharesOutstanding contextRef="AsOf2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF"> 7484370 </us-gaap:SharesOutstanding>
<TRXD:StockIssuedDuringPeriodSharesWarrantsExercisedForCashShares contextRef="From2020-01-01to2020-03-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true"/>
<TRXD:StockIssuedDuringPeriodSharesWarrantsExercisedForCashShares contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF"> 22529 </TRXD:StockIssuedDuringPeriodSharesWarrantsExercisedForCashShares>
<us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits contextRef="From2020-01-01to2020-03-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF"> 40 </us-gaap:StockIssuedDuringPeriodSharesReverseStockSplits>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2021-01-01to2021-03-31_us-gaap_PreferredStockMember" unitRef="Shares" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="From2021-01-01to2021-03-31_us-gaap_CommonStockMember" unitRef="Shares" xsi:nil="true"/>
<dei:EntityRegistrantName contextRef="From2021-01-01to2021-03-31"> TRXADE GROUP, INC. </dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="From2021-01-01to2021-03-31"> 0001382574 </dei:EntityCentralIndexKey>
<dei:DocumentType contextRef="From2021-01-01to2021-03-31"> 10-Q </dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="From2021-01-01to2021-03-31"> 2021-03-31 </dei:DocumentPeriodEndDate>
<dei:AmendmentFlag contextRef="From2021-01-01to2021-03-31"> false </dei:AmendmentFlag>
<dei:CurrentFiscalYearEndDate contextRef="From2021-01-01to2021-03-31"> --12-31 </dei:CurrentFiscalYearEndDate>
<dei:EntityCurrentReportingStatus contextRef="From2021-01-01to2021-03-31"> Yes </dei:EntityCurrentReportingStatus>
<dei:EntityInteractiveDataCurrent contextRef="From2021-01-01to2021-03-31"> Yes </dei:EntityInteractiveDataCurrent>
<dei:EntityFilerCategory contextRef="From2021-01-01to2021-03-31"> Non-accelerated Filer </dei:EntityFilerCategory>
<dei:EntitySmallBusiness contextRef="From2021-01-01to2021-03-31"> true </dei:EntitySmallBusiness>
<dei:EntityEmergingGrowthCompany contextRef="From2021-01-01to2021-03-31"> true </dei:EntityEmergingGrowthCompany>
<dei:EntityExTransitionPeriod contextRef="From2021-01-01to2021-03-31"> false </dei:EntityExTransitionPeriod>
<dei:EntityShellCompany contextRef="From2021-01-01to2021-03-31"> false </dei:EntityShellCompany>
<dei:DocumentFiscalPeriodFocus contextRef="From2021-01-01to2021-03-31"> Q1 </dei:DocumentFiscalPeriodFocus>
<dei:DocumentFiscalYearFocus contextRef="From2021-01-01to2021-03-31"> 2021 </dei:DocumentFiscalYearFocus>
<us-gaap:NotesPayableCurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 225000 </us-gaap:NotesPayableCurrent>
<us-gaap:NotesPayableCurrent contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 225000 </us-gaap:NotesPayableCurrent>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2021-01-01to2021-03-31" unitRef="Shares" decimals="INF"> 8093199 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="From2020-01-01to2020-03-31" unitRef="Shares" decimals="INF"> 7423669 </us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2021-01-01to2021-03-31" unitRef="Shares" decimals="INF"> 8093199 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="From2020-01-01to2020-03-31" unitRef="Shares" decimals="INF"> 6971427 </us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
<us-gaap:EarningsPerShareDiluted contextRef="From2021-01-01to2021-03-31" unitRef="USDPShares" decimals="INF"> -0.08 </us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareDiluted contextRef="From2020-01-01to2020-03-31" unitRef="USDPShares" decimals="INF"> 0.02 </us-gaap:EarningsPerShareDiluted>
<us-gaap:EarningsPerShareBasic contextRef="From2021-01-01to2021-03-31" unitRef="USDPShares" decimals="INF"> -0.08 </us-gaap:EarningsPerShareBasic>
<us-gaap:EarningsPerShareBasic contextRef="From2020-01-01to2020-03-31" unitRef="USDPShares" decimals="INF"> 0.03 </us-gaap:EarningsPerShareBasic>
<us-gaap:InterestExpense contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> 7264 </us-gaap:InterestExpense>
<us-gaap:InterestExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 7924 </us-gaap:InterestExpense>
<us-gaap:Depreciation contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> 1750 </us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 1250 </us-gaap:Depreciation>
<us-gaap:StockOptionPlanExpense contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> 75738 </us-gaap:StockOptionPlanExpense>
<us-gaap:StockOptionPlanExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 61997 </us-gaap:StockOptionPlanExpense>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:FairValueAdjustmentOfWarrants contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 79089 </us-gaap:FairValueAdjustmentOfWarrants>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> 98247 </us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims>
<us-gaap:IssuanceOfStockAndWarrantsForServicesOrClaims contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProvisionForDoubtfulAccounts contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:ProvisionForDoubtfulAccounts contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 9000 </us-gaap:ProvisionForDoubtfulAccounts>
<us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> 31678 </us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
<us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 23635 </us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> 1131807 </us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 94047 </us-gaap:IncreaseDecreaseInAccountsReceivable>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> 306490 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 184923 </us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInInventories contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> -787632 </us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInInventories contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 311640 </us-gaap:IncreaseDecreaseInInventories>
<us-gaap:IncreaseDecreaseInOtherReceivables contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> -6425 </us-gaap:IncreaseDecreaseInOtherReceivables>
<us-gaap:IncreaseDecreaseInOtherReceivables contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> -31517 </us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
<us-gaap:IncreaseDecreaseInOtherCurrentLiabilities contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> -20974 </us-gaap:IncreaseDecreaseInOtherCurrentLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> 109642 </us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> -14376 </us-gaap:IncreaseDecreaseInAccountsPayable>
<us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 305972 </us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
<us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> 299923 </us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
<us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 134708 </us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> -710298 </us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> -410806 </us-gaap:NetCashProvidedByUsedInOperatingActivities>
<us-gaap:PaymentsForProceedsFromProductiveAssets contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:PaymentsForProceedsFromProductiveAssets contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 23505 </us-gaap:PaymentsForProceedsFromProductiveAssets>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> -23505 </us-gaap:NetCashProvidedByUsedInInvestingActivities>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:PaymentsOfStockIssuanceCosts contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 732355 </us-gaap:PaymentsOfStockIssuanceCosts>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 5263922 </us-gaap:NetCashProvidedByUsedInFinancingActivities>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> -710298 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 4829611 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2019-12-31" unitRef="USD" decimals="0"> 2871694 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 5919578 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 5209280 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations contextRef="AsOf2020-03-31" unitRef="USD" decimals="0"> 7701305 </us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
<us-gaap:InterestPaidNet contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> 1639 </us-gaap:InterestPaidNet>
<us-gaap:InterestPaidNet contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 2348 </us-gaap:InterestPaidNet>
<us-gaap:IncomeTaxesPaidNet contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:IncomeTaxesPaidNet contextRef="From2020-01-01to2020-03-31" unitRef="USD" xsi:nil="true"/>
<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="From2021-01-01to2021-03-31" unitRef="Shares" xsi:nil="true"/>
<us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="From2020-01-01to2020-03-31" unitRef="Shares" decimals="INF"> 452242 </us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
<TRXD:NumeratorForBasicAndDilutedEpsIncomeAvailableToCommonShareholders contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> -651519 </TRXD:NumeratorForBasicAndDilutedEpsIncomeAvailableToCommonShareholders>
<TRXD:NumeratorForBasicAndDilutedEpsIncomeAvailableToCommonShareholders contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 180303 </TRXD:NumeratorForBasicAndDilutedEpsIncomeAvailableToCommonShareholders>
<us-gaap:ProceedsFromIssuanceOfDebt contextRef="From2018-10-01to2018-10-31_custom_RelatedPartyPromissoryNoteMember_custom_CommunitySpecialtyPharmacyLLCMember_custom_NikulPanchalMember" unitRef="USD" decimals="0"> 300000 </us-gaap:ProceedsFromIssuanceOfDebt>
<us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="AsOf2020-12-31" unitRef="USD" decimals="0"> 225000 </us-gaap:NotesPayableRelatedPartiesNoncurrent>
<us-gaap:NotesPayableRelatedPartiesNoncurrent contextRef="AsOf2020-03-31" unitRef="USD" decimals="0"> 225000 </us-gaap:NotesPayableRelatedPartiesNoncurrent>
<TRXD:ReductionInRightOfUseAsset contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 384110 </TRXD:ReductionInRightOfUseAsset>
<TRXD:ReductionInLeaseLiability contextRef="AsOf2021-03-31" unitRef="USD" decimals="0"> 384110 </TRXD:ReductionInLeaseLiability>
<TRXD:AmortizationOfLeaseLiability contextRef="From2021-01-01to2021-03-31" unitRef="USD" decimals="0"> 31517 </TRXD:AmortizationOfLeaseLiability>
<TRXD:AmortizationOfLeaseLiability contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 20974 </TRXD:AmortizationOfLeaseLiability>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="From2021-04-14to2021-04-15_custom_TwoThousandAndTwentyOneEquityCompensationAwardsMember_us-gaap_SubsequentEventMember_custom_MrDonaldGFellMember" unitRef="Shares" decimals="INF"> 10721 </us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="From2021-04-14to2021-04-15_custom_TwoThousandAndTwentyOneEquityCompensationAwardsMember_us-gaap_SubsequentEventMember_custom_DrPamelaTenaertsMember" unitRef="Shares" decimals="INF"> 10721 </us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures contextRef="From2021-04-14to2021-04-15_custom_TwoThousandAndTwentyOneEquityCompensationAwardsMember_us-gaap_SubsequentEventMember_custom_MrMichaelLPetersonMember" unitRef="Shares" decimals="INF"> 10721 </us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="From2021-04-14to2021-04-15_custom_TwoThousandAndTwentyOneEquityCompensationAwardsMember_us-gaap_SubsequentEventMember_custom_MrDonaldGFellMember" unitRef="USD" decimals="0"> 55000 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="From2021-04-14to2021-04-15_custom_TwoThousandAndTwentyOneEquityCompensationAwardsMember_us-gaap_SubsequentEventMember_custom_DrPamelaTenaertsMember" unitRef="USD" decimals="0"> 55000 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures contextRef="From2021-04-14to2021-04-15_custom_TwoThousandAndTwentyOneEquityCompensationAwardsMember_us-gaap_SubsequentEventMember_custom_MrMichaelLPetersonMember" unitRef="USD" decimals="0"> 55000 </us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
<TRXD:IncreaseDecreaseInDepositsForInventoryPurchases contextRef="From2021-01-01to2021-03-31" unitRef="USD" xsi:nil="true"/>
<TRXD:IncreaseDecreaseInDepositsForInventoryPurchases contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 580800 </TRXD:IncreaseDecreaseInDepositsForInventoryPurchases>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-03-31" unitRef="USD" decimals="0"> 5994424 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-03-31_us-gaap_PreferredStockMember" unitRef="USD" xsi:nil="true"/>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-03-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0"> 10 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-03-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0"> 5994414 </us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2020-01-01to2020-03-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true"/>
<TRXD:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermExpired contextRef="From2021-01-01to2021-03-31_custom_StockOptionsMember"> P0Y </TRXD:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermExpired>
<TRXD:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermExercised contextRef="From2021-01-01to2021-03-31_custom_StockOptionsMember"> P0Y </TRXD:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTermExercised>
<us-gaap:ShortTermDebtTextBlock contextRef="From2021-01-01to2021-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 2– SHORT TERM DEBT – RELATED PARTIES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In October 2018, in connection with the acquisition of Community Specialty Pharmacy, LLC, a $300,000 promissory note was issued to Nikul Panchal, a non-executive officer of the Company, accruing simple interest at the rate of 10% per annum, payable annually, and having a maturity date in October 15, 2021. In October 2019, $75,000 of the note was converted into 25,000 common shares at $3.00 per share, leaving $225,000 of principal owed under the promissory note. There was a loss recognized on this conversion of $76,500.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">At March 31, 2021 and December 31, 2020, total related party debt was $225,000.</p>
</us-gaap:ShortTermDebtTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2021-01-01to2021-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 3 – STOCKHOLDERS’ EQUITY</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>2020 Equity Compensation Awards</u></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 14, 2020, the Compensation Committee approved the grant of (a) 5,000 shares of restricted common stock to the Company’s legal counsel; and (b) 12,500 shares of restricted common stock to Howard A. Doss, the Company’s Chief Financial Officer, which shares vest at the rate of ¼<sup>th</sup> of such shares on July 1 and October 1, 2020 and January 1 and April 1, 2021. The shares have a fair value of $107,100 and the Company recognized stock-based compensation expense of $53,550 for the three months ended March 31, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>Independent Director Compensation Plan</u></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 14, 2020, the three independent members of the Board of Directors (Mr. Donald G. Fell, Dr. Pamela Tenaerts, and Mr. Michael L. Peterson), were each awarded 8,987 shares of restricted stock, which vest at the rate of ¼<sup>th</sup> of such shares on July 1 and October 1, 2020 and January 1 and April 1, 2021. The shares have a fair value of $165,000 and the Company recognized stock-based compensation expense of $82,500 for the three months ended March 31, 2021.</p>
</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<TRXD:WarrantsTextBlock contextRef="From2021-01-01to2021-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 4 – WARRANTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the three-month period ended March 31, 2021, no warrants were granted and none expired.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company uses the Black-Scholes pricing model to estimate the fair value of stock-based awards on the date of the grant.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The compensation cost related to the warrants granted was $0 and $79,089 for the three months ended March 31, 2021 and 2020, respectively.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s outstanding and exercisable warrants as of March 31, 2021 are presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Number Outstanding</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted Average Exercise Price</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Contractual Life in Years</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Intrinsic Value</b></font></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%"><font style="font-size: 10pt">Warrants Outstanding as of December 31, 2020</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">82,751</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1.33</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">2.73</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">352,951</font></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Warrants granted</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Warrants expired or forfeited</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Warrants exercised</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Warrants Outstanding as of March 31, 2021</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">82,751</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1.33</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">2.48</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">349,157</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Warrants Exercisable as of March 31, 2021</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">60,223</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1.81</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">1.34</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">232,462</font></td> <td> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
</TRXD:WarrantsTextBlock>
<us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2021-01-01to2021-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s outstanding and exercisable warrants as of March 31, 2021 are presented below:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Number Outstanding</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Weighted Average Exercise Price</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Contractual Life in Years</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Intrinsic Value</b></font></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 44%"><font style="font-size: 10pt">Warrants Outstanding as of December 31, 2020</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">82,751</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1.33</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">2.73</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 11%; text-align: right"><font style="font-size: 10pt">352,951</font></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Warrants granted</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Warrants expired or forfeited</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Warrants exercised</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Warrants Outstanding as of March 31, 2021</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">82,751</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1.33</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">2.48</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">349,157</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Warrants Exercisable as of March 31, 2021</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">60,223</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1.81</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">1.34</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">232,462</font></td> <td> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2021-01-01to2021-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the computation of basic and diluted Income (Loss) per Share:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For three months ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></p></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2021</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2020</b></font></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Numerator:</font></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 66%; text-align: justify"><font style="font-size: 10pt">Net Income (loss)</font></td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">(651,519</font></td> <td style="width: 1%"><font style="font-size: 10pt">)</font></td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">180,303</font></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Numerator for basic and diluted EPS - income available to common Shareholders</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">(651,519</font></td> <td><font style="font-size: 10pt">)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">180,303</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Denominator:</font></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Denominator for basic EPS – Weighted average shares</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">8,093,199</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">6,971,427</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Dilutive Effect of Common Stock Equivalent</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">452,242</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Denominator for diluted EPS – adjusted Weighted average shares and assumed Conversions</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">8,093,199</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">7,423,669</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Basic income (loss) per common share</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.08</font></td> <td><font style="font-size: 10pt">)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.03</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Diluted income (loss) per common share</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.08</font></td> <td><font style="font-size: 10pt">)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.02</font></td> <td> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
<us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="From2021-01-01to2021-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company’s chief operating decision makers direct the allocation of resources to operating segments based on the profitability, cash flows, and growth opportunities of each respective segment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31, 2021</b></p></td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Trxade, Inc.</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Community Specialty Pharmacy, LLC</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Integra Pharma, LLC</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Other</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Total</b></font></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 35%"><font style="font-size: 10pt">Revenue</font></td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1,236,650</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">397,896</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1,402,586</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">16,103</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">3,053,235</font></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Gross Profit</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,236,650</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">36,089</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">94,563</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">16,009</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,383,311</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Segment Assets</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">2,053,494</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(405,348</font></td> <td><font style="font-size: 10pt">)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">3,111,536</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">4,933,534</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">9,693,216</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Segment Profit (Loss)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">512,293</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(31,251</font></td> <td><font style="font-size: 10pt">)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(32,446</font></td> <td><font style="font-size: 10pt">)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(1,100,115</font></td> <td><font style="font-size: 10pt">)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(651,519</font></td> <td><font style="font-size: 10pt">)</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31, 2020</b></p></td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Trxade, Inc.</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Community Specialty Pharmacy, LLC</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Integra Pharma, LLC</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Other</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Total</b></font></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 35%"><font style="font-size: 10pt">Revenue</font></td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1,519,907</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">432,929</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">245,016</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">5,468</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">2,203,320</font></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Gross Profit</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,519,907</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">36,108</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">78,653</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">5,468</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,640,136</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Segment Assets</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">2,055,429</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">280,514</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,817,170</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">7,320,791</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">11,473,904</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Segment Profit (Loss)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">972,993</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(41,245</font></td> <td><font style="font-size: 10pt">)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(28,883</font></td> <td><font style="font-size: 10pt">)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(722,562</font></td> <td><font style="font-size: 10pt">)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">180,303</font></td> <td> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
<us-gaap:SegmentReportingDisclosureTextBlock contextRef="From2021-01-01to2021-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 9 – SEGMENT REPORTING</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company classifies its business interests into reportable segments which are Trxade, Inc., Community Specialty Pharmacy, LLC, Integra Pharma, LLC and Other. Operating segments are defined as the components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision makers in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision makers direct the allocation of resources to operating segments based on the profitability, cash flows, and growth opportunities of each respective segment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31, 2021</b></p></td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Trxade, Inc.</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Community Specialty Pharmacy, LLC</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Integra Pharma, LLC</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Other</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Total</b></font></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 35%"><font style="font-size: 10pt">Revenue</font></td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1,236,650</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">397,896</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1,402,586</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">16,103</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">3,053,235</font></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Gross Profit</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,236,650</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">36,089</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">94,563</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">16,009</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,383,311</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Segment Assets</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">2,053,494</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(405,348</font></td> <td><font style="font-size: 10pt">)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">3,111,536</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">4,933,534</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">9,693,216</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Segment Profit (Loss)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">512,293</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(31,251</font></td> <td><font style="font-size: 10pt">)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(32,446</font></td> <td><font style="font-size: 10pt">)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(1,100,115</font></td> <td><font style="font-size: 10pt">)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(651,519</font></td> <td><font style="font-size: 10pt">)</font></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>Three Months Ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31, 2020</b></p></td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Trxade, Inc.</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Community Specialty Pharmacy, LLC</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Integra Pharma, LLC</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Other</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>Total</b></font></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 35%"><font style="font-size: 10pt">Revenue</font></td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">1,519,907</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">432,929</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">245,016</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">5,468</font></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 10%; text-align: right"><font style="font-size: 10pt">2,203,320</font></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Gross Profit</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,519,907</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">36,108</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">78,653</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">5,468</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,640,136</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Segment Assets</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">2,055,429</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">280,514</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">1,817,170</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">7,320,791</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">11,473,904</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Segment Profit (Loss)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">972,993</font></td> <td> </td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(41,245</font></td> <td><font style="font-size: 10pt">)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(28,883</font></td> <td><font style="font-size: 10pt">)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(722,562</font></td> <td><font style="font-size: 10pt">)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">180,303</font></td> <td> </td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p>
</us-gaap:SegmentReportingDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="From2021-01-01to2021-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 10 – SUBSEQUENT EVENTS</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i><u>2021 Equity Compensation Awards</u></i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i> </i></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">On April 15, 2021, the Board of Directors, with the recommendation of the Compensation Committee, approved the grant of options to purchase an aggregate of 17,500 shares of our common stock to certain employees of the Company, in consideration for services to be rendered by such individuals through 2025. The options vest at the rate of ¼<sup>th</sup> of such options per year, on the first, second, third and fourth anniversaries of the grant date, subject to such option holders continuing to provide services to the Company on such dates, subject to the terms of the Company’s 2019 Amended and Restated Equity Incentive Plan (the “<u>Plan</u>”) and the option agreements entered into evidence such grants. The options were granted pursuant to, and are subject to the Plan, and have a term of five years from the grant date. The options have an exercise price of $4.76 per share, the closing price of the Company’s common stock on the date of the grant of such options.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In connection with and pursuant to the independent director compensation policy previously adopted by the Board of Directors, on April 15, 2021, the three independent members of the Board of Directors (Mr. Donald G. Fell, Dr. Pamela Tenaerts, and Mr. Michael L. Peterson), were each awarded 10,721 shares of restricted stock, valued at $55,000 ($5.13 per share) based on the closing sales price of the Company’s common stock on the Nasdaq Capital Market on the effective date of the grant, April 1, 2021, which vest at the rate of ¼<sup>th</sup> of such shares on July 1 and October 1, 2021 and January 1 and April 1, 2022, subject to such persons continuing to provide services to the Company on such dates, subject to the terms of the Plan and the Restricted Stock Grant Agreements entered into to evidence such awards.</p>
</us-gaap:SubsequentEventsTextBlock>
<us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock contextRef="From2021-01-01to2021-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 1 – ORGANIZATION AND BASIS OF PRESENTATION</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Trxade Group, Inc. (“<u>we</u>”, “<u>our</u>”, “<u>Trxade</u>”, and the “<u>Company</u>”) owns 100% of Trxade, Inc., Integra Pharma Solutions, LLC, Community Specialty Pharmacy, LLC, Alliance Pharma Solutions, LLC and Bonum Health, LLC. The merger of Trxade, Inc. and Trxade Group, Inc. occurred in May 2013. Community Specialty Pharmacy was acquired in October 2018.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Trxade, Inc., operates a web-based market platform that enables commerce among healthcare buyers and sellers of pharmaceuticals, accessories, and services.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Integra Pharma Solutions, LLC, is a licensed pharmaceutical wholesaler and sells brand, generic and non-drug products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Community Specialty Pharmacy, LLC, is an accredited independent retail pharmacy with a focus on specialty medications and a community-based model offering home delivery services to patients.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Alliance Pharma Solutions, LLC, has developed a same-day pharmaceutical delivery software – Delivmeds.com, and invested in SyncHealth MSO, LLC, a managed services organization during January 2019, which investment was divested in February 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Bonum Health, LLC was formed to hold certain telehealth assets acquired in October 2019. The “<u>Bonum Health Hub</u>” was launched in November 2019 and was expected to be operational in April 2020; however, due to the COVID-19 pandemic, at present the Company does not anticipate installations moving forward until later in 2021 at the earliest. The hub is a Health Insurance Portability and Accountability Act (HIPPA)-compliant booth planned to be installed at select independent pharmacies, with technology that connects patients to board-certified medical care through the Bonum Health mobile app and website portal. The Bonum Health mobile application is also available on a subscription basis, primarily as a stand-alone telehealth software application that can be licensed on a business-to-business (B2B) model to clients as an employment health benefit for the clients’ employees. In August 2020, Bonum Health, LLC launched a business-to-business (B2B) platform called Bonum+, which bundles telehealth, a COVID-19 risk assessment tool and a personal protective equipment (PPE) purchasing tool, through a secure mobile dashboard for corporate clients.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">MedCheks, LLC was formed in January 2021 and <font style="background-color: white">is a patient-centered, digital, precision healthcare platform that lets patients consolidate and control their health data via a digital Health Passport. The digital Health Passport allows users to share their health profile, tests and vaccinations simply and safely. Secured in a blockchain, the Health Passport includes health and vaccination status verification via a QR code (a two-dimensional machine-readable optical label), which is available for travel, entry into stadiums, concert venues, events, offices, industrial plants, warehouses, and other physical access points. MedCheks Health Passport stores all of a user’s health records securely in one place.</font></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">  </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Basis of Presentation</i> - The accompanying unaudited interim consolidated financial statements of Trxade Group, Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules of the Securities and Exchange Commission and should be read in conjunction with the audited financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities and Exchange Commission on March 29, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim periods presented have been reflected herein. The results of operations for the interim periods are not necessarily indicative of the results to be expected for the full year. Notes to the financial statements that would substantially duplicate the disclosures contained in the audited financial statements for the year ended December 31, 2020 as reported in the Company’s Annual Report on Form 10-K have been omitted.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>Income (loss) Per Common Share</i> – Basic net income per common share is computed by dividing net income available to common stockholders by the weighted average number of common shares outstanding. Diluted net income per common share is computed similar to basic net income per common share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. The dilutive effect of the Company’s options and warrants is computed using the treasury stock method.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The following table sets forth the computation of basic and diluted Income (Loss) per Share:</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="6" style="border-bottom: black 1.5pt solid"> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>For three months ended</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><b>March 31,</b></p></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2021</b></font></td> <td style="padding-bottom: 1.5pt"> </td> <td style="padding-bottom: 1.5pt"> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>2020</b></font></td> <td style="padding-bottom: 1.5pt"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"><font style="font-size: 10pt">Numerator:</font></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="width: 66%; text-align: justify"><font style="font-size: 10pt">Net Income (loss)</font></td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">(651,519</font></td> <td style="width: 1%"><font style="font-size: 10pt">)</font></td> <td style="width: 1%"> </td> <td style="width: 1%"><font style="font-size: 10pt">$</font></td> <td style="width: 14%; text-align: right"><font style="font-size: 10pt">180,303</font></td> <td style="width: 1%"> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Numerator for basic and diluted EPS - income available to common Shareholders</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">(651,519</font></td> <td><font style="font-size: 10pt">)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">180,303</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="text-align: justify"> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td style="text-align: justify"><font style="font-size: 10pt">Denominator:</font></td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Denominator for basic EPS – Weighted average shares</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">8,093,199</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">6,971,427</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Dilutive Effect of Common Stock Equivalent</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">-</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">452,242</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Denominator for diluted EPS – adjusted Weighted average shares and assumed Conversions</font></td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">8,093,199</font></td> <td> </td> <td> </td> <td> </td> <td style="text-align: right"><font style="font-size: 10pt">7,423,669</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: white"> <td><font style="font-size: 10pt">Basic income (loss) per common share</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.08</font></td> <td><font style="font-size: 10pt">)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.03</font></td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td><font style="font-size: 10pt">Diluted income (loss) per common share</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">(0.08</font></td> <td><font style="font-size: 10pt">)</font></td> <td> </td> <td><font style="font-size: 10pt">$</font></td> <td style="text-align: right"><font style="font-size: 10pt">0.02</font></td> <td> </td></tr> </table>
</us-gaap:OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock>
<us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock contextRef="From2021-01-01to2021-03-31">
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>NOTE 6 – OTHER RECEIVABLES</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In July 2020, the Company’s wholly-owned subsidiary, Integra Pharma Solutions, Inc. (“Integra”), entered into an agreement with Studebaker Defense Group, LLC (“Studebaker”) wherein Integra would pay Studebaker a down payment of $500,000 and Studebaker would deliver 180,000 boxes of nitrile gloves by August 14, 2020. Integra wired the $500,000 to Studebaker, but to date, Studebaker has not delivered the gloves or provided a refund of the deposit. In December 2020, we filed a complaint against Studebaker in Florida state court, Case No. 20-CA-010118 in the Circuit Court for the Thirteenth Judicial Circuit in Hillsborough County, for among other things, breach of contract. Studebaker did not answer the complaint, nor did counsel for Studebaker file an appearance. Accordingly, in February 2021 the Company filed for a default judgment; however, on March 22, 2021, counsel for Studebaker filed an appearance and shortly thereafter filed a motion to vacate the default judgment. A hearing on our motion for a default judgment has been set for April 27, 2021. The Company anticipates that irrespective of the outcome of such hearing on April 27, 2021, the Company will prevail on the merits; and believes Studebaker has the ability to satisfy a judgment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">In August 2020, Integra, entered into an agreement with Sandwave Group Dsn Bhd (“Sandwave”), wherein Integra would pay Sandwave a down payment of $581,250 and Sandwave’s supplier, Crecom Burj Group SDN BHD (“Crecom”), would deliver 150,000 boxes of nitrile gloves within 45 days. Integra wired the $581,250 to Sandwave, which in turn wired the purchase price to Crecom, which Crecom accepted; however, to date, Crecom has not delivered the nitrile gloves. Integra demanded return of its $581,250 and Crecom has acknowledged that Integra is entitled to a refund, but to date Crecom has failed to return Integra’s money. In February 2021, Integra filed a complaint against Crecom in Malaysia: Case No. WA-22NCC-55-02/2021 in the High Court of Malaysia at Kuala Lumpur in the Federal Territory, Malaysia for the Malaysian equivalent of breach of contract. Crecom filed an appearance on March 1, 2021. In April 2021, an Application for Summary Judgement was filed with the court, and on May 25, 2021, the Court will extract the sealed application and a copy thereof will be served on Crecom’s attorneys and Crecom will have two weeks to file an Affidavit in Reply with the court to show that there are issues to be tried and that this case must go to a full trial. We will be given 14 days thereafter to reply to that Affidavit in Reply (if there is a need to do so). In this case, we will request for a longer time to reply, given the distance involved (the court has taken note of this fact). Also at the May 25, 2021 hearing, the court will give directions on the timelines for both parties to file their written submissions/arguments in relation to the application for summary judgment If a judgment is entered against Crecom, the process of executing the judgment, and ultimately attempting to collect on the judgment, can take three to six months. The Company believes that it will prevail in the lawsuit filed; and believes Crecom has the ability to satisfy a judgment, and the steps to enforce a judgment in Malaysia, if any, may be cumbersome, time consuming or costly.</p>
</us-gaap:LoansNotesTradeAndOtherReceivablesDisclosureTextBlock>
</xbrli:xbrl>

1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/06/21  TRxADE HEALTH, Inc.               424B5                  1:701K                                   M2 Compliance LLC/FA

1 Previous Filing that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 3/29/21  TRxADE HEALTH, Inc.               10-K       12/31/20   65:4.4M                                   M2 Compliance LLC/FA
↑Top
Filing Submission 0001493152-21-009653   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)
Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
About — Privacy — Redactions — Help — Tue., May 7, 7:57:04.1pm ET